Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.

von Tresckow B, Fanale M, Ardeshna KM, Chen R, Meissner J, Morschhauser F, Moskowitz C, Zinzani PL, Giezek H, Balakumaran A, Vo TT, Raut M, Brice P.

Leuk Lymphoma. 2019 Apr 23:1-7. doi: 10.1080/10428194.2019.1602262. [Epub ahead of print]

PMID:
31012356
2.

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Al-Sawaf O, Herling CD, Holtick U, Scheid C, Cramer P, Sasse S, von Tresckow B, Tuchscherer A, Fischer K, Eichhorst B, Hallek M, Frenzel LP.

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21. No abstract available.

3.

Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group.

Bröckelmann PJ, Müller H, Kücüksarioglan E, Kaskel P, Metterlein V, Giezek H, Balakumaran A, Raut MK, Engert A, von Tresckow B.

Ann Oncol. 2019 Mar 1;30(3):490-491. doi: 10.1093/annonc/mdz004. No abstract available.

PMID:
30657863
4.

Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.

Böll B, Plütschow A, Bürkle C, Atta J, Pfreundschuh M, Feuring-Buske M, Vogelhuber M, Sökler M, Eichenauer DA, Thielen I, von Tresckow B, Fuchs M, Engert A, Borchmann P; German Hodgkin Study Group (GHSG).

Br J Haematol. 2019 Apr;185(1):42-52. doi: 10.1111/bjh.15741. Epub 2018 Dec 28.

PMID:
30592027
5.

Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.

von Tresckow B, Sayehli C, Aulitzky WE, Goebeler ME, Schwab M, Braz E, Krauss B, Krauss R, Hermann F, Bartz R, Engert A.

Eur J Haematol. 2019 Feb;102(2):163-173. doi: 10.1111/ejh.13188. Epub 2019 Jan 7.

PMID:
30347469
6.

Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.

von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.

Lancet Haematol. 2018 Oct;5(10):e462-e473. doi: 10.1016/S2352-3026(18)30140-6.

PMID:
30290903
7.

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.

Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B.

Br J Haematol. 2018 Nov;183(3):400-410. doi: 10.1111/bjh.15539. Epub 2018 Aug 30.

PMID:
30168134
8.

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A.

Blood. 2018 Oct 4;132(14):1519-1525. doi: 10.1182/blood-2018-02-836437. Epub 2018 Jul 31.

PMID:
30064977
9.

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).

Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N.

Cochrane Database Syst Rev. 2018 Jul 12;7:CD012556. doi: 10.1002/14651858.CD012556.pub2. Review.

PMID:
30001476
10.

Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.

Sasse S, Goergen H, Plütschow A, Böll B, Eichenauer DA, Fuchs M, Behringer K, Zijlstra JM, Greil R, Markova J, Topp MS, Meissner J, Neubauer A, Baues C, Engert A, Borchmann P, von Tresckow B.

J Clin Oncol. 2018 Sep 1;36(25):2603-2611. doi: 10.1200/JCO.2018.78.7192. Epub 2018 Jul 10.

PMID:
29989855
11.

Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.

Collins GP, Rueda A, Salles G, von Tresckow B, Zaja F.

Leuk Lymphoma. 2018 Sep;59(9):2113-2120. doi: 10.1080/10428194.2017.1421762. Epub 2018 Jan 16.

PMID:
29334819
12.

Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.

Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B.

Cochrane Database Syst Rev. 2017 May 25;5:CD007941. doi: 10.1002/14651858.CD007941.pub3. Review.

13.

Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.

Blank O, von Tresckow B, Monsef I, Specht L, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2017 Apr 27;4:CD007110. doi: 10.1002/14651858.CD007110.pub3. Review.

14.

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087.

J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25.

15.

Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.

Hude I, Sasse S, Bröckelmann PJ, von Tresckow B, Momotow J, Engert A, Borchmann S.

Br J Haematol. 2018 Jun;181(6):837-840. doi: 10.1111/bjh.14705. Epub 2017 Apr 25. No abstract available.

PMID:
28439879
16.

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.

Bröckelmann PJ, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall SJ, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A.

Ann Oncol. 2017 Jun 1;28(6):1352-1358. doi: 10.1093/annonc/mdx072.

PMID:
28327958
17.

Novel agents in classical Hodgkin lymphoma.

Borchmann S, von Tresckow B.

Leuk Lymphoma. 2017 Oct;58(10):2275-2286. doi: 10.1080/10428194.2017.1300898. Epub 2017 Mar 20.

PMID:
28318345
18.

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.

Bröckelmann PJ, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, Markova J, Meissner J, Kerkhoff A, Ludwig WD, Fuchs M, Borchmann P, Engert A.

J Clin Oncol. 2017 May 1;35(13):1444-1450. doi: 10.1200/JCO.2016.71.3289. Epub 2017 Feb 27.

PMID:
28240973
19.

Treatment of relapsed and refractory Hodgkin Lymphoma.

von Tresckow B, Moskowitz CH.

Semin Hematol. 2016 Jul;53(3):180-5. doi: 10.1053/j.seminhematol.2016.05.010. Epub 2016 May 12. Review.

20.

Current developments in the treatment of early-stage classical Hodgkin lymphoma.

Borchmann S, von Tresckow B, Engert A.

Curr Opin Oncol. 2016 Sep;28(5):377-83. doi: 10.1097/CCO.0000000000000314. Review.

PMID:
27455136
21.

Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.

von Tresckow B, Morschhauser F, Szer J, Eichenauer DA, Abramson JS, Sureda A, Engert A.

Leuk Lymphoma. 2017 Jan;58(1):222-225. Epub 2016 May 17. No abstract available.

PMID:
27184350
22.

PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis.

Sickinger MT, von Tresckow B, Kobe C, Borchmann P, Engert A, Skoetz N.

Crit Rev Oncol Hematol. 2016 May;101:86-92. doi: 10.1016/j.critrevonc.2016.03.005. Epub 2016 Mar 6. Review.

PMID:
26971064
23.

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.

Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P.

Blood. 2016 May 5;127(18):2189-92. doi: 10.1182/blood-2015-11-681064. Epub 2016 Feb 1.

24.

Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.

Eichenauer DA, Goergen H, Plütschow A, Wongso D, Behringer K, Kreissl S, Thielen I, Halbsguth T, Bröckelmann PJ, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A.

Leukemia. 2016 Jun;30(6):1425-7. doi: 10.1038/leu.2015.321. Epub 2015 Nov 20. No abstract available.

PMID:
26585412
25.

Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group.

Bröckelmann PJ, Goergen H, Fuchs M, Kriz J, Semrau R, Baues C, Kobe C, Behringer K, Eichenauer DA, von Tresckow B, Klimm B, Halbsguth T, Wongso D, Plütschow A, Haverkamp H, Dietlein M, Eich HT, Stein H, Diehl V, Borchmann P, Engert A.

Br J Haematol. 2015 Nov;171(4):547-56. doi: 10.1111/bjh.13646. Epub 2015 Aug 27.

PMID:
26310520
26.

Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Fuchs M, von Tresckow B, Böll B, Behringer K, Diehl V, Eich HT, Borchmann P, Engert A.

J Clin Oncol. 2015 Sep 10;33(26):2857-62. doi: 10.1200/JCO.2014.60.4363. Epub 2015 Aug 3.

PMID:
26240235
27.

Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.

Haverkamp H, Böll B, Eichenauer DA, Sasse S, Fuchs M, Borchmann P, Diehl V, Engert A, von Tresckow B.

J Clin Oncol. 2015 Aug 1;33(22):2430-6. doi: 10.1200/JCO.2014.60.4264. Epub 2015 Jun 22.

PMID:
26101245
28.

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.

von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S, Aquino R, Kotoulek S, de Boer CJ, Engert A.

Clin Cancer Res. 2015 Apr 15;21(8):1843-50. doi: 10.1158/1078-0432.CCR-14-1845. Epub 2015 Jan 27.

29.

Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.

Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N.

Cochrane Database Syst Rev. 2015 Jan 9;1:CD010533. doi: 10.1002/14651858.CD010533.pub2. Review.

PMID:
25572491
30.

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie.

Lancet. 2015 Apr 11;385(9976):1418-27. doi: 10.1016/S0140-6736(14)61469-0. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396.

PMID:
25539730
31.

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.

Oki Y, Buglio D, Zhang J, Ying Y, Zhou S, Sureda A, Ben-Yehuda D, Zinzani PL, Prince HM, Harrison SJ, Kirschbaum M, Johnston PB, Shen A, von Tresckow B, Younes A.

Blood Cancer J. 2014 Aug 8;4:e236. doi: 10.1038/bcj.2014.58. No abstract available.

32.

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis.

Rancea M, von Tresckow B, Monsef I, Engert A, Skoetz N.

Crit Rev Oncol Hematol. 2014 Oct;92(1):1-10. doi: 10.1016/j.critrevonc.2014.04.003. Epub 2014 May 2. Review.

PMID:
24855908
33.

An update on emerging drugs for Hodgkin lymphoma.

von Tresckow B, Diehl V.

Expert Opin Emerg Drugs. 2014 Jun;19(2):215-24. doi: 10.1517/14728214.2014.912277. Epub 2014 Apr 21. Review.

PMID:
24749769
34.

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, Klimm B, Diehl V, Sasse S, Rothe A, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A.

Blood. 2014 Mar 13;123(11):1658-64. doi: 10.1182/blood-2013-07-512657. Epub 2014 Jan 29.

35.

Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group.

Böll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R, von Tresckow B, Eichenauer DA, Sasse S, Fuchs M, Behringer K, Klimm BC, Naumann R, Diehl V, Engert A, Borchmann P.

J Clin Oncol. 2013 Dec 10;31(35):4431-7. doi: 10.1200/JCO.2013.49.8246. Epub 2013 Nov 4.

PMID:
24190119
36.

Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions.

Klimm B, Goergen H, Fuchs M, von Tresckow B, Böll B, Meissner J, Glunz A, Diehl V, Eich HT, Engert A, Borchmann P.

Ann Oncol. 2013 Dec;24(12):3070-6. doi: 10.1093/annonc/mdt413. Epub 2013 Oct 22.

PMID:
24148816
37.

Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant.

von Tresckow B, Müller H, Eichenauer DA, Glossmann JP, Josting A, Böll B, Klimm B, Sasse S, Fuchs M, Borchmann P, Engert A.

Leuk Lymphoma. 2014 Aug;55(8):1922-4. doi: 10.3109/10428194.2013.854888. Epub 2014 Jan 28. No abstract available.

PMID:
24138304
38.

Refractory Hodgkin lymphoma.

von Tresckow B, Engert A.

Curr Opin Oncol. 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. Review.

PMID:
23942291
39.

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.

Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2013 Jun 20;(6):CD009411. doi: 10.1002/14651858.CD009411.pub2. Review.

PMID:
23784872
40.

Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.

von Tresckow B, Boell B, Eichenauer D, Beschorner D, Knop S, Goebeler ME, Chemnitz JM, Hallek M, Engert A, Huebel K.

Leuk Lymphoma. 2014 Mar;55(3):695-7. doi: 10.3109/10428194.2013.809074. Epub 2013 Jul 29. No abstract available.

PMID:
23713484
41.

Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up.

Rancea M, Engert A, von Tresckow B, Halbsguth T, Behringer K, Skoetz N.

Dtsch Arztebl Int. 2013 Mar;110(11):177-83, 183e1-3. doi: 10.3238/arztebl.2013.0177. Epub 2013 Mar 15.

42.

ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.

Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P.

J Clin Oncol. 2013 Apr 20;31(12):1522-9. doi: 10.1200/JCO.2012.45.4181. Epub 2013 Mar 18.

PMID:
23509310
43.

Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.

Sasse S, Rothe A, Goergen H, Eichenauer DA, Lohri A, Kreher S, Jäger U, Bangard C, Kuhnert G, Böll B, von Tresckow B, Engert A.

Leuk Lymphoma. 2013 Oct;54(10):2144-8. doi: 10.3109/10428194.2013.775434. Epub 2013 Mar 27.

PMID:
23402268
44.

The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant.

von Tresckow B, Engert A.

Expert Rev Hematol. 2012 Oct;5(5):483-6. doi: 10.1586/ehm.12.41.

PMID:
23146052
45.

Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.

von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A.

J Clin Oncol. 2012 Mar 20;30(9):907-13. doi: 10.1200/JCO.2011.38.5807. Epub 2012 Jan 23.

PMID:
22271480
46.

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma.

Böll B, Bredenfeld H, Görgen H, Halbsguth T, Eich HT, Soekler M, Markova J, Keller U, Graeven U, Kremers S, Geissler M, Trenn G, Fuchs M, von Tresckow B, Eichenauer DA, Borchmann P, Engert A.

Blood. 2011 Dec 8;118(24):6292-8. doi: 10.1182/blood-2011-07-368167. Epub 2011 Sep 13.

47.

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Böll B, von Tresckow B, Nogová L, Borchmann P, Engert A.

Blood. 2011 Oct 20;118(16):4363-5. doi: 10.1182/blood-2011-06-361055. Epub 2011 Aug 9.

48.

The role of autologous transplantation in Hodgkin lymphoma.

von Tresckow B, Engert A.

Curr Hematol Malig Rep. 2011 Sep;6(3):172-9. doi: 10.1007/s11899-011-0091-0. Review.

PMID:
21567226
49.

Activity of cetuximab as single agent in a patient with relapsed multiple myeloma.

Böll B, Eichenauer DA, Von Tresckow B, Peine D, Hallek M, Engert A, Hübel K.

Leuk Lymphoma. 2010 Mar;51(3):562-4. doi: 10.3109/10428190903580428. No abstract available.

PMID:
20095962
50.

Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.

Böll B, Eltaib F, Reiners KS, von Tresckow B, Tawadros S, Simhadri VR, Burrows FJ, Lundgren K, Hansen HP, Engert A, von Strandmann EP.

Clin Cancer Res. 2009 Aug 15;15(16):5108-16. doi: 10.1158/1078-0432.CCR-09-0213. Epub 2009 Aug 11.

Supplemental Content

Loading ...
Support Center